{"id":77408,"date":"2023-10-27T07:30:01","date_gmt":"2023-10-27T11:30:01","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/is-abbott-stock-undervalued-at-95\/"},"modified":"2023-10-27T07:30:05","modified_gmt":"2023-10-27T11:30:05","slug":"is-abbott-stock-undervalued-at-95","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=77408","title":{"rendered":"Is Abbott Stock Undervalued At $95?"},"content":{"rendered":"<div>\n<p><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/\">Abbott<\/strong> (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared to the last five-year average of 5.4x, and we believe investors will likely be better off picking ABT for robust gains in the long run.<\/p>\n<p>The company reported revenue of $10.1 billion, reflecting a 2.6% decline from the prior year period and above the $9.8 billion street estimate. Its adjusted earnings of $1.14 per share were down 1% y-o-y and above the consensus estimate of $1.11 per share. In this note, we discuss Abbott\u2019s stock performance, key takeaways from its recent results, and valuation.<\/p>\n<p>ABT stock has seen a decline of 15% from levels of $110 in early January 2021 to around $94 now, vs. an increase of about 10% for the S&amp;P 500 over this roughly 3-year period. However, the decrease in ABT stock has been far from consistent. Returns for the stock were 29% in 2021, -22% in 2022, and -15% in 2023. In comparison, returns for the S&amp;P 500 have been 27% in 2021, -19% in 2022, and 9% in 2023 &#8211; indicating that <strong>ABT underperformed the S&amp;P<\/strong> in 2022 and 2023.<\/p>\n<p>In fact, <strong>consistently beating the S&amp;P 500<\/strong> &#8211; in good times and bad &#8211; has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT.<\/p>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p>In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has <strong>outperformed the S&amp;P 500 each year<\/strong> over the same period. <strong>Why is that?<\/strong> As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index, less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.<\/p>\n<p>Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could ABT face a similar situation as it did in 2022 and 2023 and <strong>underperform the S&amp;P<\/strong> over the next 12 months &#8211; or will it see a recovery? From a valuation perspective, ABT stock looks undervalued. We estimate <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/no-login-required\/rlOQzYfL\/Abbott-ABT-Valuation-Is-ABT-Stock-Expensive-Or-Cheap-?fromforbesandarticle=trefis231027\">Abbott\u2019s Valuation<\/strong> to be $117 per share, reflecting a solid 25% upside from its current levels of $94. Our forecast is based on a 26x P\/E multiple for ABT and expected earnings of $4.44 on a per-share and adjusted basis for the full year 2023. The company raised its earnings outlook to now be in the range of $4.42 and $4.46 (vs. the $4.30 and $4.40 range earlier).<\/p>\n<p>Abbott\u2019s revenue of $10.1 billion in Q3 was down 3% y-o-y. The company reported a 17% jump in Medical Device segment sales, Nutrition was up 16%, and Established Pharmaceuticals saw a 3% rise in revenue. Growth in these segments was more than offset by a 33% fall in Diagnostics revenues due to lower demand for COVID-19 testing. Excluding the Covid-19 tests, the Diagnostics sales were up 10.1%. There are rising concerns over increased adoption of glucagon-like peptide-1 (GLP-1) drugs on glucose monitoring devices. However, Abbott\u2019s management stated that they do not perceive GLP-1 drugs to put pressure on their FreeStyle range of CGM devices.<\/p>\n<p>The company saw its adjusted operating income margin contract 100 bps y-o-y to 22.9%. Despite lower revenues and margin contraction, Abbott reported only a 1% decline in the bottom line to $1.14 on a per-share and adjusted basis in Q3\u201923. This can be attributed to lower taxes and a 1% decline in total shares outstanding.<\/p>\n<p>While ABT stock looks undervalued, it is helpful to see how <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/ABT\/topic\/peer-comparisons\">Abbott\u2019s Peers<\/strong> fare on metrics that matter. You will find other valuable comparisons for companies across industries at <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/topic\/peer-comparisons\">Peer Comparisons<\/strong><strong>.<\/strong><\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/10\/27\/is-abbott-stock-undervalued-at-95\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared to the last five-year average of 5.4x, and we believe investors will likely be better off picking ABT for robust gains in the long run. The company reported revenue of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":77409,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-77408","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Is Abbott Stock Undervalued At $95? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=77408\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Abbott Stock Undervalued At $95? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=77408\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-27T11:30:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-27T11:30:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/10\/1698406203_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1353\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=77408#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=77408\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Is Abbott Stock Undervalued At $95?\",\"datePublished\":\"2023-10-27T11:30:01+00:00\",\"dateModified\":\"2023-10-27T11:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=77408\"},\"wordCount\":599,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=77408#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=77408\",\"url\":\"https:\/\/ifintechworld.com\/?p=77408\",\"name\":\"Is Abbott Stock Undervalued At $95? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-10-27T11:30:01+00:00\",\"dateModified\":\"2023-10-27T11:30:05+00:00\",\"description\":\"Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=77408#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=77408\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=77408#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Abbott Stock Undervalued At $95?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Is Abbott Stock Undervalued At $95? | iFintechWorld","description":"Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=77408","og_locale":"en_US","og_type":"article","og_title":"Is Abbott Stock Undervalued At $95? | iFintechWorld","og_description":"Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared","og_url":"https:\/\/ifintechworld.com\/?p=77408","og_site_name":"iFintechWorld","article_published_time":"2023-10-27T11:30:01+00:00","article_modified_time":"2023-10-27T11:30:05+00:00","og_image":[{"width":1353,"height":900,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/10\/1698406203_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=77408#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=77408"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Is Abbott Stock Undervalued At $95?","datePublished":"2023-10-27T11:30:01+00:00","dateModified":"2023-10-27T11:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=77408"},"wordCount":599,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=77408#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=77408","url":"https:\/\/ifintechworld.com\/?p=77408","name":"Is Abbott Stock Undervalued At $95? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-10-27T11:30:01+00:00","dateModified":"2023-10-27T11:30:05+00:00","description":"Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=77408#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=77408"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=77408#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Is Abbott Stock Undervalued At $95?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/77408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77408"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/77408\/revisions"}],"predecessor-version":[{"id":77410,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/77408\/revisions\/77410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/77409"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}